Next Article in Journal
Blue-Print Autophagy: Potential for Cancer Treatment
Previous Article in Journal
New Cyclotetrapeptides and a New Diketopiperzine Derivative from the Marine Sponge-Associated Fungus Neosartorya glabra KUFA 0702
Previous Article in Special Issue
Time Dependency of Chemodiversity and Biosynthetic Pathways: An LC-MS Metabolomic Study of Marine-Sourced Penicillium
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2016, 14(7), 137; doi:10.3390/md14070137

From Discovery to Production: Biotechnology of Marine Fungi for the Production of New Antibiotics

1
GEOMAR Helmholtz Centre for Ocean Research Kiel, Marine Natural Products Chemistry Research Unit, GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Am Kiel-Kanal 44, Kiel 24106, Germany
2
Faculty of Mathematics and Natural Sciences, University of Kiel, Christian-Albrechts-Platz 4, Kiel 24118, Germany
*
Author to whom correspondence should be addressed.
Academic Editors: Samuel Bertrand and Olivier Grovel
Received: 8 June 2016 / Revised: 6 July 2016 / Accepted: 12 July 2016 / Published: 21 July 2016
View Full-Text   |   Download PDF [6280 KB, uploaded 21 July 2016]   |  

Abstract

Filamentous fungi are well known for their capability of producing antibiotic natural products. Recent studies have demonstrated the potential of antimicrobials with vast chemodiversity from marine fungi. Development of such natural products into lead compounds requires sustainable supply. Marine biotechnology can significantly contribute to the production of new antibiotics at various levels of the process chain including discovery, production, downstream processing, and lead development. However, the number of biotechnological processes described for large-scale production from marine fungi is far from the sum of the newly-discovered natural antibiotics. Methods and technologies applied in marine fungal biotechnology largely derive from analogous terrestrial processes and rarely reflect the specific demands of the marine fungi. The current developments in metabolic engineering and marine microbiology are not yet transferred into processes, but offer numerous options for improvement of production processes and establishment of new process chains. This review summarises the current state in biotechnological production of marine fungal antibiotics and points out the enormous potential of biotechnology in all stages of the discovery-to-development pipeline. At the same time, the literature survey reveals that more biotechnology transfer and method developments are needed for a sustainable and innovative production of marine fungal antibiotics. View Full-Text
Keywords: marine biotechnology; transfer to stirred tank reactor; full fermentative process; semi-synthesis; biological derivatisation; filamentous fungi; bioprocess development; heterologous expression; genetic and metabolic engineering; downstream processing marine biotechnology; transfer to stirred tank reactor; full fermentative process; semi-synthesis; biological derivatisation; filamentous fungi; bioprocess development; heterologous expression; genetic and metabolic engineering; downstream processing
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Silber, J.; Kramer, A.; Labes, A.; Tasdemir, D. From Discovery to Production: Biotechnology of Marine Fungi for the Production of New Antibiotics. Mar. Drugs 2016, 14, 137.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top